BSX
Boston Scientific Corporation
NYSE · Healthcare · Medical - Devices · US
$47.80
+1.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 21.0B | 20.1B | 16.7B | 14.2B | 12.7B |
| Cost of Revenue | 6.1B | 6.2B | 6.5B | 5.4B | 5.0B |
| Gross Profit | 14.9B | 13.9B | 10.3B | 8.8B | 7.7B |
| Operating Expenses | |||||
| R&D Expense | 2.2B | 2.1B | 1.6B | 1.4B | 1.3B |
| SG&A Expense | 7.2B | 6.9B | 6.0B | 5.2B | 4.5B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.1B | 943.0M | 33.0M | 46.0M | 47.0M |
| Total Operating Expenses | 10.4B | 9.9B | 7.6B | 6.7B | 5.9B |
| Cost and Expenses | 16.5B | 16.1B | 14.1B | 12.1B | 10.9B |
| Operating Income (EBIT) | 4.5B | 4.0B | 2.6B | 2.2B | 1.8B |
| Non-Operating | |||||
| Interest Income | — | — | 107.0M | 22.0M | 10.0M |
| Interest Expense | 363.0M | 349.0M | 387.0M | 272.0M | 464.0M |
| Net Interest Income | (363.0M) | (349.0M) | (280.0M) | (250.0M) | (454.0M) |
| Other Non-Op Income/Expense | (645.0M) | (586.0M) | (353.0M) | (196.0M) | (683.0M) |
| Non-Operating Income (excl Interest) | 116.0M | 237.0M | (34.0M) | (76.0M) | 219.0M |
| EBT (Pre-Tax Income) | 3.9B | 3.4B | 2.3B | 2.0B | 1.1B |
| Income Tax Expense | 193.0M | 493.0M | 436.0M | 393.0M | 443.0M |
| Bottom Line | |||||
| Net Income | 3.7B | 2.9B | 1.9B | 1.6B | 698.0M |
| Earnings from Cont. Ops | 3.7B | 2.9B | 1.8B | 1.6B | 698.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.7B | 2.9B | 1.9B | 1.6B | 642.0M |
| Per Share | |||||
| Basic EPS | $2.48 | $1.96 | $1.26 | $1.08 | $0.45 |
| Diluted EPS | $2.46 | $1.94 | $1.25 | $1.07 | $0.45 |
| Revenue Per Share | $14.21 | $13.56 | $11.38 | $9.80 | $8.87 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.4B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.4B |
| Profitability Metrics | |||||
| EBITDA | 5.7B | 5.1B | 3.9B | 3.5B | 2.7B |
| D&A | 1.3B | 1.4B | 1.3B | 1.2B | 1.1B |
| EBIT | 4.4B | 3.7B | 2.7B | 2.3B | 1.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026